# Collagen Hair Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/collagen-hair-randomized-trial-evidence-review
Category: evidence-review
Summary: Collagen Hair Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed bi
Last reviewed: 2026-07-26
Reviewed by: Migaku Evidence Review
# Collagen Hair Randomized Trial: What the Evidence Says

## Quick Answer

Collagen Hair Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 preclinical study, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Chitosan in aesthetic practice: A clinical narrative review of skin, scar, and scalp applications | preclinical study | 4 | 2026-07-01 | 10.1016/j.jpra.2026.05.018 |
| Microneedle‐Assisted Delivery of PEGylated Recombinant Human Fusion Collagen for Androgenetic Alopecia: Preclinical and Pilot Clinical Evidence | research article | 4 | 2026-06-04 | 10.1111/jocd.70931 |

## What The Sources Report

- Where human evidence is limited, we emphasize mechanistic plausibility and research needs rather than extrapolating to prescriptive protocols. [Sydorchuk Olena (2026); evidence level 4]
- Design: This is a clinical narrative review intended to support evidence‑informed aesthetic practice. [Sydorchuk Olena (2026); evidence level 4]
- Emerging evidence indicates that extracellular matrix (ECM) components, particularly type III collagen, function as dynamic signaling reservoirs essential for hair follicle biology. [Jin Meitong (2026); evidence level 4]
- This early-phase study provides initial evidence for the efficacy and safety of PEG-rhCol-F, supporting a novel dual-mechanism strategy for AGA management. [Jin Meitong (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For collagen hair randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Sydorchuk Olena (2026). Chitosan in aesthetic practice: A clinical narrative review of skin, scar, and scalp applications. DOI: 10.1016/j.jpra.2026.05.018. PMCID: PMC13251474. PMID: 42281907. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13251474/
- Jin Meitong (2026). Microneedle‐Assisted Delivery of PEGylated Recombinant Human Fusion Collagen for Androgenetic Alopecia: Preclinical and Pilot Clinical Evidence. DOI: 10.1111/jocd.70931. PMCID: PMC13238325. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13238325/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.